Starting with the Brestri Aerosphere COPD inhaler (pending regulatory approval), AstraZeneca intends to transition all of its MDIs to this technology by 2030. “The work we are doing with ...

A breast cancer drug - which keeps the disease stable for up to four times longer than the previous treatment - will be ...

AZ is also developing a rival triple therapy inhaler, Breztri Aerosphere (budesonide+glycopyrrolate+formoterol fumarate), which is already approved in the US in COPD and is in late-stage ...

"Before, there was that balance of 'what is time worth?' And now, that's taken that stress away somewhat." ...